Woodline Partners LP Biomarin Pharmaceutical Inc Transaction History

Woodline Partners LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $13 Million - $15 Million	150,013 Added 177.06%	234,736 $20.3 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $7.43 Million - $9.94 Million	84,723 New	84,723 $8.24 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $16.3 Million - $19.2 Million	-198,476 Reduced 49.23%	204,693 $17.4 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $28.8 Million - $35 Million	403,169 New	403,169 $33.4 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $33.3 Million - $41.5 Million	-447,654 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $32.1 Million - $40.9 Million	447,654 New	447,654 $39.6 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $10.7 Million - $16.7 Million	-134,149 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $1.68 Million - $2.28 Million	-23,558 Reduced 14.94%	134,149 $11.3 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $10.1 Million - $13.6 Million	157,707 New	157,707 $13.3 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.